100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
NUR 333 Final Exam Spring 2017 $24.49   Add to cart

Exam (elaborations)

NUR 333 Final Exam Spring 2017

 1 view  0 purchase
  • Course
  • Institution

NUR 333 Final Exam Spring 2017

Preview 4 out of 37  pages

  • December 5, 2022
  • 37
  • 2022/2023
  • Exam (elaborations)
  • Questions & answers
avatar-seller
NUR 333 Final Exam-Spring 2017
Chronic Neuromuscular Disorders
Guillain-Barre Syndrome
Etiology and Pathophysiology
 ASCENDING PARALYSIS
 Autoimmune disorder preceded by infection, trauma or surgery
 Acute, rapidly progressing, and potentially fatal form of polyneuritis
Clinical Manifestations
 Symptoms appear SYMMETRICAL and develop in days to weeks
 Paresthesia (numbness and tingling) in the extremities
 Hypotonia (reduced muscle tone) and areflexia (lack of reflexes – in arms and legs)
 Orthostatic hypotension, hypertension, and vagal responses (bradycardia, heart block, asystole)
 Bowel and bladder dysfunction, diaphoresis, facial flushing
 Pain –paresthesias, muscular aches and cramps, and hyperesthesia (increased sensitivity)
 Respiratory failure as paralysis progresses upwards
 Disease does not affect level of consciousness, cognition or pupillary constriction/dilation – mind is intact
Collaborative Care
 During acute phase:
– Monitor the ascending paralysis; assess respiratory function; monitor arterial blood gases (ABGs); and assess
the gag, corneal, and swallowing reflexes. Reflexes are usually decreased or absent.
 Carefully assess swallowing and gag reflex and take measures to prevent aspiration – HOB elevated
 Plasma exchange (plasmapheresis): removes circulating antibodies thought to be responsible for the disease –
monitor for hypovolemia, hypokalemia – is only useful during first 2 weeks
– Plasma is separated from the whole blood and blood cells are returned to the patient without the plasma
– Interventions: weighing the patient before and after procedure, caring for the shunt or venous access site and
preventing complications, provide information and reassurance
– Cannot go back to corticosteroids after plasmapheresis
 High dose immunoglobin therapy (Sandoglobulin)
– ADE: chills, mild fever, myalgia, headache, anaphylaxis, aseptic meningitis, retinal necrosis

Myasthenia Gravis
Etiology and Pathophysiology
 FACIAL/MUSCLE WEAKNESS – eyes, eyelids, swallowing, speaking, breathing
 Alterations/blockage of acetylcholine at neuromuscular junction prevents muscle contraction
 Autoimmune disease with fluctuating weakness of certain skeletal muscle groups
Clinical Manifestations
 Muscles are generally the strongest in the morning and become exhausted with continued activity – periods of rest
are necessary
 Difficulty breathing (weakness to chest wall muscles), impaired speech and swallow, eyelid drooping (ptosis), double
vision, fatigue, weakness
 Exacerbations can be caused by emotional stress, trauma, temperature extremes, hypokalemia
 Prognosis: some patients have short-term remissions, others stabilize, others may have severe
Myasthenic Crisis
 Acute exacerbation of muscle weakness, triggered by infection, surgery, emotional distress, drug overdose or
inadequate drugs. The major complications of MG result form muscle weakness in areas that affect breathing and
swallowing = intubation and ventilator!! Emergency!!
– Can results in aspiration, respiratory insufficiency and respiratory infection
– Keep bag-valve-mask equipment for oxygen administration, and suction equipment at bedside
– Symptoms improve with Tensilon Test (ACh is injected and breathing improves)
Cholinergic Crisis
 Symptoms worsen with Tensilon Test – INCREASES WEAKNESS and does not improve muscle tone
 Too much cholinesterase inhibitor drugs

,Diagnosis
 Blood test to detect the presence of immune molecules or acetylcholine receptor antibodies
 Tensilon test: reveals improved muscle contraction after IV injection of Edrophonium chloride (Tensilon)
– In case of adverse effects of Tensilon, Atropine should be administered
Collaborative Care
 Drug Therapy:
– Anticholinesterase agents (neostigmine, pyridostigmine) – help improve neuromuscular transmission and
increase muscle strength - report nausea to HCP
– Corticosteroids (Prednisone): is used to suppress the immune response
 Plasmapheresis: short term improvement indicated for patients in crisis or in preparation for surgery when
corticosteroids must be avoided – cannot go back to corticosteroids after doing plasmapheresis – last resort
 Surgery: thymus gland removal may cure individuals

Multiple Sclerosis
 Chronic progressive, degenerative disorder of the CNS – onset between 20 – 50 years old
 Related to infectious (viral), immunologic, and genetic factors
Clinical Manifestations
 Numbness, weakness, tingling feeling in arms and legs
 Weakness or paralysis of the limbs, the trunk, or the head; diplopia (double vision); scanning speech; and spasticity
of the muscles that are chronically affected, gait and balance problems
 Numbness and tingling, patchy blindness (scotomas), blurred vision, vertigo, tinnitus, decreased hearing
 Lhermitte’s sign: electric shock radiating down the spine or into the limbs with flexion of the neck.
 Fatigue that is aggravated by heat, humidity, deconditioning, and medication side effects
 Constipation, spastic bladder  incontinence and dribbling, flaccid bladder resulting in urinary retention
 Short attention span, poor judgement and memory difficulty – patient remains intellectually intact
 Speech and swallowing symptoms: slurred or difficult-to-understand speech, trouble chewing and swallowing,
fatigue is a common and bothersome symptom of MS progresses. It is often worse in the late afternoon
Diagnostic Studies
 MRI of the brain and spinal cord may show plaques, inflammation, atrophy, and tissue breakdown/destruction
 CSF analysis (lumbar puncture/spinal tap) may show an  immunoglobulin G
 To be diagnosed with MS patient must have:
– Evidence of at least two inflammatory demyelinating lesions in at least two different locations in CNS
– Damage or an attack occurring at different times (usually 1 month or more apart)
– All other possible diagnoses ruled out
Collaborative Care
 No cure for MS, care is aimed at treating the disease process and providing systematic relief
 Drug Therapy: Medications used to slow the progression of MS are taken on a long-term basis
– Immunosuppressants (methotrexate), and adrenocorticotropic hormone
– Corticosteroids: used to reduce the inflammation that spikes during a relapse
– Immunomodulator (Copaxone, β-interferon): used to prevent relapses and modify progression
 ADE may include flushing and SOB after injection
 β-interferon (Avonex, Betaseron): rotate injection site with each dose, assess for depression and
suicidal ideation, wear sunscreen, flu-like symptoms common after initiation of therapy. Blood tests to
monitor liver enzymes.
– Gilenya: prevents lymphocytes from damaging CNS, need to have chicken pox before taking drug, monitor BP
regularly, avoid pregnancy – monitor for bradycardia
Nursing Management
 During an acute exacerbation the patient may be immobile and confined to bed – prevent major complications such
as respiratory infection, UTI and pressure ulcers
 Patient teaching should be focused on building general resistance to illness, including avoiding fatigue, extremes of
hot or cold



2

,Musculoskeletal Disorders
Osteoporosis (fragile bone disease)  calcium in bones,  calcium in blood
 Chronic, progressive metabolic bone disease marked by: low bone mass, deterioration of bone tissue
 Leads to increased bone fragility – falls  fractures
 Known as “silent thief” – slowly robs you of skeletal resources
 More common in women because they have lower calcium intake, less bone mass, bone resorption begins earlier
and becomes more rapid at menopause, pregnancy and breastfeeding, and live longer than men
 Additional risks for fractures: smoking, low body weight, prior fractures
 Risk factors: >65 yrs old, female, low body weight, family history, calcium/Vit D deficiency
Etiology and Pathophysiology
 Risk factors: excessive use of alcohol (>2 a day), low testosterone in men, diet low in calcium/vitamin D deficiency,
specific diseases (malabsorption disease), certain drugs (long use of corticosteroids), thyroid replacement, heparin
 Peak bone mass (by age 20) determined by heredity, nutrition, exercise and hormone function. Bone loss after 35-
40 years is inevitable
 Osteoblast – bone deposit/ formation – bone building
 Osteoclast – resorb bone (remodeling) – osteoclasts exceed osteoblasts in osteoporosis - breaks down bone tissue
 Long term corticosteroid use is a major contributor to osteoporosis
 Calcium and phosphorus abnormalities – porous brittle bones and  fractures
Clinical Manifestations
 Occurs in spine, hips, and wrists
 First manifestations are back pain or spontaneous fractures
 Gradual loss of height leading to kyphosis or “dowager’s hump”
Diagnostic Studies
 Bone mineral density (BMD) – determined by peak bone mass and amount of bone loss
– Quantitative ultrasound (QUS): measures bone density with sound waves in kneecap, heel, and shin
– Dual-energy x-ray absorptiometry (DXA): measures bone density in spine, hips and forearm
 T-scores
– T score above -1.0 = normal bone density
– T score between -1.0 and -2.5 = osteopenia
– T score of -2.5 or lower = osteoporosis
 Z score: compares with someone own age and ethnicity: anything less than -2.0
Collaborative Care
 Care focuses on proper nutrition, calcium supplementation, exercise, prevention of falls and fractures, and drugs
 Proper nutrition
– 1000 mg/day of calcium in women 19-50, men 19-70 years
– 1200 mg/day of calcium for women 51+, men 71+ years
– Milk, cheese, yogurts, salmon, oysters, broccoli, almonds, turnip greens, ice cream, sardines, spinach
 Calcium supplements – take in divided doses with food (easier to absorb)
– Calcium carbonate (Tums) – take with meals, 40% elemental calcium
– Calcium citrate – less dependent on stomach acid, 20% elemental calcium
– Vitamin D necessary for calcium absorption/function; bone formation. Sunlight for 20 minutes, supplemental
(800-1000IU/day) for postmenopausal, older adults, homebound, minimal sun exposure
 Exercise
– Weight-bearing exercise: buildup and maintain bone mass,  strength, coordination (walking, hiking)
– Walking 30 minutes, 3x a week is recommended
– Quit smoking and cur down on alcohol intake
 Prevention of fractures – fall prevention
 Vertebroplasty: bone cement is injected into collapsed vertebrae to stabilize, does not correct deformity
 Kyphoplasty: air bladder is inserted and inflated to regain vertebral height
Drug therapy
 Bisphosphonates: inhibit bone resorption
– Common side effects: anorexia, weight loss, gastritis
– Alendronate (Fosamax): once per week oral tablet
3

, – Proper administration: take will full glass of water, take on empty stomach, 30 minutes before food or other
meds, remain upright for at least 30 minutes, – patient MUST be able to sit up to be a candidate for this
medication
– Prevents bone loss,  bone density
– Rare/serious side effect: jaw osteonecrosis
 Calcitonin: inhibits bone resorption
– Give IM form at night to minimize side effects of nausea and facial flushing
– Alternate nostrils when using nasal form – nausea does not occur with nasal spray
 Teriparatide (Forteo): synthetic PTH
– Used to treat men with osteoporosis and postmenopausal women who are at  risk of fractures
– First drug to stimulate new bone formation
– Side effects include leg cramps and dizziness
 Denosumab (Prolia)
– Postmenopausal women, subcutaneous injection every 6 months
– For patients at high risk of fractures

Osteomalacia (Rickets)
 Caused by vitamin D deficiency, resulting in decalcification and softening of bones
 Softening of bone leads to gross deformities
Etiology and Pathophysiology
 Lack of vitamin D: inadequate production, lack of sunlight (UV therapy), dietary deficiency, abnormal metabolism
 Causes: liver disease, kidney disease, vitamin D disturbances, drug therapy (Dilantin, Fluoride, barbiturate),
malabsorption syndrome, inflammatory bowel disease
 Obese patients are at  risk due to inadequate calcium intake, decreased physical activity, vitamin D deficiency,
coexisting chronic conditions
Clinical Manifestations
 Bone pain/tenderness, difficulty rising from chair, and difficulty walking
 Muscle fatigue, weakness, weight loss, progressive deformities of spine (kyphosis) and extremities
Diagnostic Studies
 Decreased serum calcium or phosphorus levels;  alkaline phosphatase
 X-ray: Looser’s transformation zones (ribbons of decalcification in bone found on x-ray) are diagnostic of
osteomalacia.
Collaborative Care
 Aimed at correcting Vitamin D deficiency
 Calcium, phosphate, and/or vitamin D supplements
 Encourage dietary ingestion of eggs, meat, oily fish, and milk and breakfast cereals fortified with calcium and
vitamin D. Exposure to sunlight (and ultraviolet rays), perform weight- bearing exercise
Osteomyelitis
 An infection of the bone, bone marrow, and surrounding soft tissue that results in in inflammation, necrosis, and
formation of new bone
 Hematogenous osteomyelitis: due to blood borne spread of infection
– Caused by pathogens carried in the blood from other sites of infection
 Contiguous-focus osteomyelitis from contamination from bone surgery, open fracture, or traumatic injury (GSW)
 Osteomyelitis with vascular insufficiency, seen most commonly among patients with diabetes and peripheral
vascular disease, most commonly affecting the feet
 Patients can become septic
Etiology and Pathophysiology
 Exogenous: infection enters from outside as in an open fracture
 Endogenous (hematogenous): organisms travel by blood from other sites of infection (bacteremia)
 The pelvis, tibia, and vertebrae, which are vascular-rich sites of bone, are the most common sites of infection
 Osteomyelitis may also occur in the presence of a foreign object in the body (implant, orthopedic prosthetic device
– total joint replacement)
 Microorganism grows and ultimately results in ischemia and bone dies
4

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller zipporah01. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $24.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

78861 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$24.49
  • (0)
  Add to cart